Institut Pasteur, French National Reference Center and WHO Collaborating Center for Listeria, Microbes and Host Barriers Group, Université Paris Descartes, Centre d’Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, Paris, France.
Clin Infect Dis. 2012 Jan 15;54(2):240-8. doi: 10.1093/cid/cir803. Epub 2011 Nov 18.
Little is known about Listeria monocytogenes-associated bone and joint infections. Only case reports of this infection have been published.
Retrospective study of culture-proven bone and joint cases reported to the French National Reference Center for Listeria from 1992 to 2010.
Forty-three patients were studied: 61% were men, and the median age was 72 (range, 16-89); 24 patients exhibited comorbidities (56%). Thirty-six patients (84%) had orthopedic implant devices: prosthetic joints (n = 34) or internal fixation (n = 2); the median time after insertion was 9 years (0.1-22). Subacute infection was more frequent (median, 4 weeks [range, 2-100], 74%) than acute infection (<7 days, 23%), with nonspecific clinical features; 45% of patients had no fever. Blood cultures were positive in 3 of 19 cases. Isolate polymerase chain reaction genogrouping revealed 4 patterns: IVb (21 of 42, 50%), IIa (17 of 42, 40%), IIb (2 of 42, 5%), and IIc (2 of 42, 5%). Five groups of strains with similar pulsotype patterns were identified without an epidemiological link. Antibiotics, primarily amoxicillin (80%) with aminoglycosides (48%), were prescribed for a median duration of 15 weeks (range, 2-88). Eighteen patients (50%) underwent prosthesis replacement; all were successful after median follow-up of 10 months (range, 1-75). Five of 13 patients for whom material was not removed had protracted infection despite prolonged antibiotherapy; 3 of these patients later underwent prosthesis replacement with sustained recovery.
Osteoarticular listeriosis primarily involves prosthetic joints and occurs in immunocompromised patients. It requires intensive treatment with antibiotherapy and usually requires implant removal or replacement for cure.
李斯特菌相关性骨和关节感染的相关信息较少。目前仅报道了几例此类感染的病例报告。
对法国李斯特菌国家参考中心 1992 年至 2010 年报告的经培养证实的骨和关节病例进行回顾性研究。
共研究了 43 例患者:61%为男性,中位年龄为 72 岁(范围为 16-89 岁);24 例患者存在合并症(56%)。36 例(84%)患者存在矫形植入物:人工关节(n=34)或内固定(n=2);植入后中位时间为 9 年(0.1-22 年)。亚急性感染(中位时间为 4 周[范围为 2-100 天],74%)比急性感染(<7 天,23%)更为常见,且临床表现不具特异性;45%的患者无发热。19 例血培养中 3 例阳性。分离物聚合酶链反应基因分型显示 4 种模式:IVb(42 例中的 21 例,50%)、IIa(42 例中的 17 例,40%)、IIb(42 例中的 2 例,5%)和 IIc(42 例中的 2 例,5%)。未发现具有流行病学联系的 5 组具有相似脉冲模式的菌株。使用了抗生素,主要是阿莫西林(80%)联合氨基糖苷类药物(48%),中位疗程为 15 周(范围为 2-88 周)。18 例(50%)患者接受了假体置换;所有患者在中位 10 个月(范围为 1-75 个月)的随访后均成功。13 例未取出感染材料的患者中,5 例尽管接受了长期抗生素治疗,但仍存在持续性感染;其中 3 例随后接受了假体置换,均获得了持续的康复。
骨关节炎李斯特菌感染主要涉及人工关节,发生于免疫功能低下的患者中。需要强化抗生素治疗,通常需要去除或置换植入物以达到治愈。